The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

Article activity feed

1. Version published to 10.1016/j.celrep.2021.109679

   Sep 1, 2021
2. 

   ScreenIT

   Apr 3, 2021

   SciScore for 10.1101/2021.04.01.438035: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   All antibodies (except LY-CoV555) were produced as full IgG1 antibodies as described (Barlev-Gross et al., 2021; Rosenfeld et al., 2021), expressed using ExpiCHO™ Expression system (Thermoscientific, USA) and purified on HiTrap Protein-A column (GE healthcare, UK).	IgG1 suggested: None
   For assessment of binding to S1 variants or mutated RBD, antibodies were captured on Protein-A or anti-Fab CH1 sensors (FAB2G) and incubated with recombinant S1 (WT, B.1.1.7 …

   SciScore for 10.1101/2021.04.01.438035: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   All antibodies (except LY-CoV555) were produced as full IgG1 antibodies as described (Barlev-Gross et al., 2021; Rosenfeld et al., 2021), expressed using ExpiCHO™ Expression system (Thermoscientific, USA) and purified on HiTrap Protein-A column (GE healthcare, UK).	IgG1 suggested: None
   For assessment of binding to S1 variants or mutated RBD, antibodies were captured on Protein-A or anti-Fab CH1 sensors (FAB2G) and incubated with recombinant S1 (WT, B.1.1.7 or B.1.351) or recombinant RBD (WT or mutated) for 180 sec and then transferred to buffer containing wells for additional 60 sec.	anti-Fab suggested: None
   For epitope binning, MD65 antibody was biotinylated, immobilized on streptavidin sensor, incubated with a fixed concentration of WT rS1 (20 μg/ml) to reach saturation, washed and incubated with non-labeled LY-CoV555 for 180 sec.	MD65 suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Isolation and characterization of the MD29, MD65 and MD62 mAbs, targeting epitopes I-III on the RBD as previously reported.	MD65 suggested: RRID:CVCL_MD65)
   MD29 and MD65 were used as positive and negative controls, respectively.	MD29 suggested: RRID:CVCL_MD29)
   Titer of stock was determined by plaque assay using Vero E6 cells.	Vero E6 suggested: RRID:CVCL_XD71)
   Software and Algorithms
   Sentences	Resources
   The following His-tagged recombinant proteins were purchased from Sino Biologicals: B.1.1.7 rS1-SARS-CoV-2 spike S1 [Δ 69-70; Δ 144; N501Y; A570D; D614G; P681H], cat#40591-V08H12; B.1.351 rS1-SARS-CoV-2 spike S1 [K417N; E484K; N501Y; D614G], cat#40591-V08H10; spike RBD[N501Y] cat#40592-V08H82; spike RBD[S477N] cat#40592-V08H46; spike RBD[E484K] cat#40592-V08H84; spike RBD[N439K] cat#40592-V08H14; spike RBD[K417N] cat#40592-V08H59; spike RBD[Y453F] cat#40592-V08H80.	Sino Biologicals suggested: None
   Area under curve (AUC) was calculated for each binding curve, using GraphPad Prism 5, and percent binding was calculated compared to the WT protein, representing 100% binding.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)
   The identity of the B.1.1.7 strain was confirmed using NGS.	NGS suggested: (PM4NGS, RRID:SCR_019164)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • No funding statement was detected.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.04.01.438035 on bioRxiv

   Apr 1, 2021